<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04541355</url>
  </required_header>
  <id_info>
    <org_study_id>20208</org_study_id>
    <secondary_id>NCI-2020-05752</secondary_id>
    <nct_id>NCT04541355</nct_id>
  </id_info>
  <brief_title>Sodium Thiosulfate for the Prevention of Ototoxicity in Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck Undergoing Chemoradiation With Cisplatin</brief_title>
  <official_title>A Phase II Study of Sodium Thiosulfate (STS) for Prevention of Ototoxicity in Patients With Locally Advanced Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Concurrent Chemoradiation With Cisplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hyunseok Kang, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial investigates how well sodium thiosulfate works in preventing ototoxicity&#xD;
      (hearing loss/damage) in patients with squamous cell cancer of the head and neck that has&#xD;
      spread to nearby tissue or lymph nodes (locally advanced) who are undergoing a&#xD;
      chemoradiation. Sodium thiosulfate is a type of medication used to treat cyanide poisoning&#xD;
      and to help lessen the side effects from cisplatin. Chemotherapy drugs, such as cisplatin,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells, by&#xD;
      stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with&#xD;
      radiation therapy may kill more tumor cells. The purpose of this trial is to find out whether&#xD;
      it is feasible to give sodium thiosulfate 4 hours after each cisplatin infusion along with&#xD;
      standard of care radiation therapy in patients with head and neck cancer. Giving sodium&#xD;
      thiosulfate after cisplatin may help decrease the risk of hearing loss.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To establish feasibility of intravenous sodium thiosulfate (STS) after each dose of&#xD;
      concurrent cisplatin in patients with locally advanced head and neck squamous cell carcinoma&#xD;
      undergoing definitive radiotherapy.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the rate of grade &gt;= 2 change from baseline based on Common Terminology&#xD;
      Criteria for Adverse Events (CTCAE) version 5 with use of STS after concurrent chemoradiation&#xD;
      with cisplatin 3 months post-treatment.&#xD;
&#xD;
      II. To determine the rate of tinnitus measured by Patient Reported Outcomes (PRO)-CTCAE with&#xD;
      use of STS 3 months post-treatment.&#xD;
&#xD;
      III. To describe patient reported outcomes with STS measured with PRO-CTCAE for selected&#xD;
      oral, gastrointestinal (GI), neurologic and perceptual symptoms.&#xD;
&#xD;
      IV. To describe patient reported outcomes measured with Hearing Handicap Inventory for Adults&#xD;
      - Screening (HHIA-S) compared to results from standard NRG Oncology head and neck trials&#xD;
      (such as Radiation Therapy Oncology Group (RTOG) 1016).&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 2 groups per treating physician's discretion.&#xD;
&#xD;
      COHORT A: Patients undergo standard of care radiation therapy daily for 6-7 weeks. Patients&#xD;
      receive cisplatin intravenously (IV) on day 1. Between 4-5 hours after each cisplatin&#xD;
      infusion, patients also receive sodium thiosulfate IV over 1-2 hours on day 1. Treatment&#xD;
      repeats every 7 days for up to 7 cycles in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      COHORT B: Patients undergo standard of care radiation therapy daily for 6-7 weeks. Patients&#xD;
      receive high-dose cisplatin IV on day 1. Between 4-5 hours after each cisplatin infusion,&#xD;
      patients also receive sodium thiosulfate IV over 1-2 hours on day 1. Treatment repeats every&#xD;
      21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for up to 3&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 14, 2020</start_date>
  <completion_date type="Anticipated">March 6, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 6, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who successfully completed planned treatment</measure>
    <time_frame>Up to 7 days after the last dose of sodium thiosulfate (STS)</time_frame>
    <description>Evaluated as the successful completion of 5 weekly cisplatin or 2 high dose cisplatin without any extended treatment related delays more than 7 days. Overall successful completion is defined as completion by at least 75% of patients in each cohorts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of treatment-related adverse events</measure>
    <time_frame>3 months after completion of chemoradiation</time_frame>
    <description>Treatment-related adverse events will be classified using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of high grade ototoxicity</measure>
    <time_frame>3 months after completion of chemoradiation</time_frame>
    <description>Defined by change of grade &gt;= 2 based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (for patients on a monitoring program with audiogram in each cohort. Will report the proportion of patients experiencing high-grade toxicity with exact binomial 95% confidence intervals.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8</condition>
  <condition>Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8</condition>
  <condition>Locally Advanced Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Locally Advanced Hypopharyngeal Squamous Cell Carcinoma</condition>
  <condition>Locally Advanced Laryngeal Squamous Cell Carcinoma</condition>
  <condition>Locally Advanced Oral Cavity Squamous Cell Carcinoma</condition>
  <condition>Locally Advanced Oropharyngeal Squamous Cell Carcinoma</condition>
  <condition>Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8</condition>
  <condition>Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8</condition>
  <condition>Stage III Hypopharyngeal Carcinoma AJCC v8</condition>
  <condition>Stage III Laryngeal Cancer AJCC v8</condition>
  <condition>Stage III Lip and Oral Cavity Cancer AJCC v8</condition>
  <condition>Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8</condition>
  <condition>Stage IV Hypopharyngeal Carcinoma AJCC v8</condition>
  <condition>Stage IV Laryngeal Cancer AJCC v8</condition>
  <condition>Stage IV Lip and Oral Cavity Cancer AJCC v8</condition>
  <condition>Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8</condition>
  <condition>Stage IVA Hypopharyngeal Carcinoma AJCC v8</condition>
  <condition>Stage IVA Laryngeal Cancer AJCC v8</condition>
  <condition>Stage IVA Lip and Oral Cavity Cancer AJCC v8</condition>
  <condition>Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8</condition>
  <condition>Stage IVB Hypopharyngeal Carcinoma AJCC v8</condition>
  <condition>Stage IVB Laryngeal Cancer AJCC v8</condition>
  <condition>Stage IVB Lip and Oral Cavity Cancer AJCC v8</condition>
  <condition>Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8</condition>
  <condition>Stage IVC Hypopharyngeal Carcinoma AJCC v8</condition>
  <condition>Stage IVC Laryngeal Cancer AJCC v8</condition>
  <condition>Stage IVC Lip and Oral Cavity Cancer AJCC v8</condition>
  <condition>Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8</condition>
  <arm_group>
    <arm_group_label>Cohort A: Weekly Cisplatin + STS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo standard of care radiation therapy daily for 6-7 weeks. Patients receive cisplatin IV on day 1. Between 4-5 hours after each cisplatin infusion, patients also receive sodium thiosulfate IV over 1-2 hours on day 1. Treatment repeats every 7 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: High Dose Cisplatin + STS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo standard of care radiation therapy daily for 6-7 weeks. Patients receive high-dose cisplatin IV on day 1. Between 4-5 hours after each cisplatin infusion, patients also receive sodium thiosulfate IV over 1-2 hours on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort A: Weekly Cisplatin + STS</arm_group_label>
    <arm_group_label>Cohort B: High Dose Cisplatin + STS</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone''s Chloride</other_name>
    <other_name>Peyrone''s Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hearing Handicap Inventory for Adults - Screening</intervention_name>
    <description>Patient self-assessment questionnaire to measure probability of hearing impairment</description>
    <arm_group_label>Cohort A: Weekly Cisplatin + STS</arm_group_label>
    <arm_group_label>Cohort B: High Dose Cisplatin + STS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Radiation therapy will be delivered according to the standard of care</description>
    <arm_group_label>Cohort A: Weekly Cisplatin + STS</arm_group_label>
    <arm_group_label>Cohort B: High Dose Cisplatin + STS</arm_group_label>
    <other_name>Cancer Radiotherapy</other_name>
    <other_name>Irradiate</other_name>
    <other_name>Irradiated</other_name>
    <other_name>Irradiation</other_name>
    <other_name>Radiation</other_name>
    <other_name>Radiation Therapy, Not otherwise specified (NOS)</other_name>
    <other_name>Radiotherapeutics</other_name>
    <other_name>Radiotherapy</other_name>
    <other_name>RT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Thiosulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort A: Weekly Cisplatin + STS</arm_group_label>
    <arm_group_label>Cohort B: High Dose Cisplatin + STS</arm_group_label>
    <other_name>Cyanide Antidote Package</other_name>
    <other_name>Disodium Thiosulfate</other_name>
    <other_name>S-Hydril</other_name>
    <other_name>Sodium Hyposulfate</other_name>
    <other_name>Sodium Thiosulfate Pentahydrate</other_name>
    <other_name>Sodium Thiosulphate</other_name>
    <other_name>Sodothiol</other_name>
    <other_name>Thiosulfate, Sodium, Pentahydrate</other_name>
    <other_name>Thiosulfuric Acid Disodium Salt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Questionnaire based on Patient Reported Outcomes-Criteria for Adverse Events (PRO-CTCAE) (PRO-CTCAE)</intervention_name>
    <description>Selected oral, GI, neurologic and perceptual symptoms are reported by patient</description>
    <arm_group_label>Cohort A: Weekly Cisplatin + STS</arm_group_label>
    <arm_group_label>Cohort B: High Dose Cisplatin + STS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants must have histologically or cytologically confirmed locoregionally&#xD;
             advanced squamous cell carcinomas of mucosal surfaces of head and neck who are being&#xD;
             treated with concurrent chemoradiation with cisplatin&#xD;
&#xD;
          2. Participants must be eligible for cisplatin-based concurrent chemotherapy in&#xD;
             conjunction with at least 6 weeks of daily fractionated radiation therapy&#xD;
&#xD;
          3. Age &gt;=18 years&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 (Karnofsky &gt;= 50%)&#xD;
&#xD;
          5. Demonstrates adequate organ function as defined below:&#xD;
&#xD;
               1. Absolute neutrophil count &gt;= 1,000/microliter (mcL)&#xD;
&#xD;
               2. Platelets &gt;= 100,000/mcL&#xD;
&#xD;
               3. Total bilirubin within normal institutional limits, unless elevated due to&#xD;
                  Gilbert's syndrome and direct bilirubin is within normal limits&#xD;
&#xD;
               4. Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase (SGOT))&#xD;
                  =&lt; 3 X institutional upper limit of normal&#xD;
&#xD;
               5. Alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase (SGPT)) =&lt; 3 X&#xD;
                  institutional upper limit of normal&#xD;
&#xD;
               6. Creatinine =&lt; 1.5 x within institutional upper limit of normal OR creatinine&#xD;
                  clearance glomerular filtration rate (GFR) &gt;= 60 mL/min/1.73 m^2, calculated&#xD;
                  using the Cockcroft-Gault equation, unless data exists supporting safe use at&#xD;
                  lower kidney function values, no lower than 30 mL/min/1.73 m^2&#xD;
&#xD;
          6. Ability to understand a written informed consent document, and the willingness to sign&#xD;
             it&#xD;
&#xD;
          7. Individuals with a prior or concurrent malignancy whose natural history or treatment&#xD;
             does not have the potential to interfere with the safety or efficacy assessment of the&#xD;
             investigational regimen are eligible for this trial&#xD;
&#xD;
          8. The effects of sodium thiosulfate (STS) on the developing human fetus are unknown. For&#xD;
             this reason and because cisplatin used in this trial are known to be teratogenic,&#xD;
             women of childbearing potential and men must agree to use adequate contraception such&#xD;
             as hormonal and/or barrier method of birth control for the duration of study&#xD;
             participation and for 3 months after last administration of study treatment. Should a&#xD;
             woman become pregnant or suspect she is pregnant while she or her partner is&#xD;
             participating in this study, she should inform her treating physician immediately. Men&#xD;
             treated or enrolled on this protocol must also agree to use adequate contraception&#xD;
             prior to the study, for the duration of study participation, and 3 months after last&#xD;
             administration of study treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants that are not eligible for cisplatin-based chemoradiation for reasons such&#xD;
             as chronic kidney disease, severe hearing loss, and severe peripheral neuropathy&#xD;
&#xD;
          2. Uncontrolled inter-current illness or psychiatric illness/social situation that would&#xD;
             limit compliance with study requirements&#xD;
&#xD;
          3. Has known hypersensitivity to cisplatin, sodium thiosulfate or any of its excipients&#xD;
&#xD;
          4. Has profound hearing impairment at baseline and cannot hear a sound below 90 decibels&#xD;
             (dB)&#xD;
&#xD;
          5. Participants with uncompensated congestive heart failure New York Heart Association&#xD;
             (NYHA) class 3 or above&#xD;
&#xD;
          6. Participants who cannot get secure venous access using either a Mediport or a&#xD;
             peripherally inserted central catheter (PICC) line for safe administration of&#xD;
             intravenous sodium thiosulfate&#xD;
&#xD;
          7. Pregnant women are excluded from this study because cisplatin is a cytotoxic agent&#xD;
             with the potential for teratogenic or abortifacient effects. Because there is an&#xD;
             unknown but potential risk for adverse events in nursing infants secondary to&#xD;
             treatment of the mother with cisplatin or sodium thiosulfate, breastfeeding should be&#xD;
             discontinued if the mother is treated with either agent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyunseok Kang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 1, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Hyunseok Kang, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Laryngeal Neoplasms</mesh_term>
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Lip Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Ototoxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sodium thiosulfate</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Antidotes</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

